Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nippon Shinyaku Licenses Prulifloxacin Marketing Rights To Lee’s Pharmaceutical

This article was originally published in PharmAsia News

Executive Summary

Kyoto-based Nippon Shinyaku announced March 3 a licensing agreement on antibacterial drug prulifloxacin with Hong Kong biopharmaceutical company Lee's Pharmaceutical Holdings, which gives Lee's the exclusive marketing rights in China for antibacterial drugs containing prulifloxacin. Nippon Shinyaku will receive an undisclosed upfront payment, milestone payments based on sales achievement and product royalties. An oral broad spectrum fluoroquinolone antibiotic developed by Nippon Shinyaku, prulifloxacin is marketed in Japan by Meiji Seika with the name Sword and by Angelini with the name Unidrox in Europe. (Click here for more - Japanese language

You may also be interested in...



One Drug Outfit On China's Periphery Stands Out From The Crowd Through Innovation

HONG KONG - A famous ability to copy, combined with a chronic shortage of innovation, has long defined China's pharmaceutical industry

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.

UsernamePublicRestriction

Register

SC071268

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel